Learning a patient's specific situation might help overcome adherence barriers.
Lisa Holle, PharmD, BCOP, FHOPA
Advertisement
Articles by Lisa Holle, PharmD, BCOP, FHOPA
Betrixaban has been approved by the FDA for patients at risk for thromboembolisms.
Advertisement
Latest Updated Articles
Betrixaban for Prophylaxis of Venous ThromboembolismPublished: June 4th 2018 | Updated:
Duvelisib for Relapsed or Refractory CLL/SLLPublished: January 22nd 2019 | Updated:
Opinion: Pharmacists Are Best Suited to Improve AdherencePublished: February 26th 2019 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
2
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
3
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
4
What TrumpRx Means for Independent Pharmacies and Their Patients
5
